Use of Mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis

Use of Mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis

In contrast to patients with viral hepatitis, patients with nonalcoholic fatty liver disease (NAFLD) can progress to hepatocellular carcinoma during the initial stages of liver fibrosis. Development and implementation of noninvasive methods for diagnosis and progression prediction are important for...

Full description

Bibliographic Details
Main Authors: Yoshihiro Kamada, Masafumi Ono, Hideyuki Hyogo, Hideki Fujii, Yoshio Sumida, Makoto Yamada, Kojiroh Mori, Saiyu Tanaka, Tomohiro Maekawa, Yusuke Ebisutani, Akiko Yamamoto, Shinji Takamatsu, Masashi Yoneda, Norifumi Kawada, Kazuaki Chayama, Toshiji Saibara, Tetsuo Takehara, Eiji Miyoshi, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG‐NAFLD)
Format: Article
Language:English
Published: Wolters Kluwer Health/LWW 2017-10-01
Series:Hepatology Communications
Online Access:https://doi.org/10.1002/hep4.1080

Internet

https://doi.org/10.1002/hep4.1080

Similar Items